NASDAQ:CLCD - CoLucid Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$46.5250 0.00 (0.00 %)
(As of 05/24/2018 10:06 AM ET)
Previous Close$46.5250
Today's Range$46.5250 - $46.5250
52-Week Range$5.26 - $46.65
VolumeN/A
Average Volume708,479 shs
Market Capitalization$895.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals logoCoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Receive CLCD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLCD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:CLCD
CUSIPN/A
Phone+1-781-3652596

Debt

Debt-to-Equity RatioN/A
Current Ratio11.31
Quick Ratio11.30

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-83.51%
Return on Assets-70.62%

Miscellaneous

Employees7
Outstanding Shares19,280,000

CoLucid Pharmaceuticals (NASDAQ:CLCD) Frequently Asked Questions

What is CoLucid Pharmaceuticals' stock symbol?

CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."

How were CoLucid Pharmaceuticals' earnings last quarter?

CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) announced its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.79). View CoLucid Pharmaceuticals' Earnings History.

When did CoLucid Pharmaceuticals IPO?

(CLCD) raised $55 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and William Blair was co-manager.

Has CoLucid Pharmaceuticals been receiving favorable news coverage?

News articles about CLCD stock have trended positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CoLucid Pharmaceuticals earned a news sentiment score of 0.25 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of CoLucid Pharmaceuticals?

Shares of CLCD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CoLucid Pharmaceuticals' stock price today?

One share of CLCD stock can currently be purchased for approximately $46.5250.

How big of a company is CoLucid Pharmaceuticals?

CoLucid Pharmaceuticals has a market capitalization of $895.94 million. CoLucid Pharmaceuticals employs 7 workers across the globe.

How can I contact CoLucid Pharmaceuticals?

CoLucid Pharmaceuticals' mailing address is 222 3rd St, CAMBRIDGE, MA 02142-1102, United States. The biopharmaceutical company can be reached via phone at +1-781-3652596.


MarketBeat Community Rating for CoLucid Pharmaceuticals (CLCD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote "Outperform" if you believe CLCD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLCD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CoLucid Pharmaceuticals (NASDAQ:CLCD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AHold
Consensus Rating Score: N/AN/AN/A2.25
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$47.8333
Price Target Upside: N/AN/AN/A3.42% upside

CoLucid Pharmaceuticals (NASDAQ:CLCD) Consensus Price Target History

Price Target History for CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals (NASDAQ:CLCD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2017BarclaysDowngradeOverweight ➝ Equal Weight$45.00N/AView Rating Details
1/18/2017BTIG ResearchSet Price TargetBuy$52.00N/AView Rating Details
1/18/2017William BlairDowngradeOutperform ➝ Market PerformN/AView Rating Details
1/18/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$49.00 ➝ $46.50N/AView Rating Details
10/24/2016Stifel NicolausBoost Price TargetBuy$30.00 ➝ $40.00N/AView Rating Details
9/19/2016Ladenburg ThalmannSet Price TargetBuy$57.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

CoLucid Pharmaceuticals (NASDAQ:CLCD) Earnings History and Estimates Chart

Earnings by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals (NASDAQ CLCD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/20169/30/2016($0.79)($0.79)ViewN/AView Earnings Details
8/10/2016Q2($0.84)($1.06)ViewN/AView Earnings Details
5/11/2016Q1($0.7250)($0.85)ViewN/AView Earnings Details
3/2/2016Q4 2015($0.64)($0.74)ViewN/AView Earnings Details
11/10/2015Q3($0.63)($0.59)ViewN/AView Earnings Details
8/12/2015Q2 2015($0.40)($1.17)ViewN/AView Earnings Details
6/18/2015Q1 2015($0.50)($0.47)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CoLucid Pharmaceuticals (NASDAQ:CLCD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CoLucid Pharmaceuticals (NASDAQ CLCD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 64.17%
Insider Trading History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Insider Trading History for CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals (NASDAQ CLCD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2017Linda C HoganInsiderSell2,580$35.18$90,764.40718View SEC Filing  
1/5/2017Thomas P MathersCEOSell1,502$34.78$52,239.56258,021View SEC Filing  
1/3/2017Bernice KucaInsiderSell772$36.25$27,985.0040,086View SEC Filing  
1/3/2017Matthew D DallasCFOSell1,473$36.25$53,396.2540,128View SEC Filing  
12/5/2016Linda C HoganInsiderSell2,583$37.77$97,559.91719View SEC Filing  
12/5/2016Thomas P. MathersCEOSell1,502$38.75$58,202.50View SEC Filing  
12/1/2016Bernice KucaInsiderSell772$35.22$27,189.84View SEC Filing  
12/1/2016Matthew D. DallasCFOSell1,473$35.17$51,805.41View SEC Filing  
11/7/2016Linda C HoganInsiderSell1,862$28.56$53,178.72185View SEC Filing  
11/7/2016Thomas P MathersCEOSell1,502$28.57$42,912.14250,422View SEC Filing  
11/1/2016Linda C HoganInsiderSell719$30.00$21,570.00719View SEC Filing  
10/5/2016Linda C HoganInsiderSell2,581$37.22$96,064.82719View SEC Filing  
10/5/2016Thomas P MathersCEOSell1,502$37.08$55,694.16248,169View SEC Filing  
9/14/2016Thomas P MathersCEOSell6,000$23.32$139,920.00244,714View SEC Filing  
9/9/2016A/S NovoMajor ShareholderBuy100,000$20.00$2,000,000.003,156,563View SEC Filing  
9/7/2016Thomas P MathersCEOSell6,502$21.72$141,223.44256,916View SEC Filing  
9/6/2016Linda C HoganInsiderSell48,736$19.87$968,384.3236,452View SEC Filing  
8/31/2016Raymond SkwierczynskiInsiderSell150$10.86$1,629.0047View SEC Filing  
8/19/2016Raymond SkwierczynskiInsiderSell508$8.41$4,272.28197View SEC Filing  
8/10/2016Raymond SkwierczynskiInsiderSell508$8.30$4,216.40705View SEC Filing  
8/5/2016Thomas P MathersCEOSell1,502$8.31$12,481.62254,662View SEC Filing  
8/3/2016Domain Partners Vi, L.P.Major ShareholderSell153,028$8.45$1,293,086.60View SEC Filing  
7/29/2016Raymond SkwierczynskiInsiderSell508$9.09$4,617.721,213View SEC Filing  
7/20/2016Raymond SkwierczynskiInsiderSell508$8.97$4,556.761,721View SEC Filing  
7/11/2016Raymond SkwierczynskiInsiderSell508$9.10$4,622.802,229View SEC Filing  
6/30/2016Raymond SkwierczynskiInsiderSell516$7.01$3,617.162,737View SEC Filing  
6/20/2016Raymond SkwierczynskiInsiderSell1,008$6.80$6,854.40View SEC Filing  
6/6/2016Thomas P MathersCEOSell1,502$7.25$10,889.50250,156View SEC Filing  
4/28/2016Vi Associates L.P. DpMajor ShareholderSell235$6.96$1,635.60View SEC Filing  
8/25/2015Thomas P MathersCEOBuy7,500$7.10$53,250.007,500View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy1,300,000$10.00$13,000,000.00View SEC Filing  
5/11/2015Arthur M PappasDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CoLucid Pharmaceuticals (NASDAQ CLCD) News Headlines

Source:
DateHeadline
Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as PartnerFormer CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner
www.bizjournals.com - April 10 at 9:10 AM
Analyzing CoLucid Pharmaceuticals (CLCD) and Amicus Therapeutics (FOLD)Analyzing CoLucid Pharmaceuticals (CLCD) and Amicus Therapeutics (FOLD)
www.americanbankingnews.com - February 2 at 9:08 AM
Head-To-Head Review: Marinus Pharmaceuticals (MRNS) & CoLucid Pharmaceuticals (CLCD)Head-To-Head Review: Marinus Pharmaceuticals (MRNS) & CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - February 2 at 5:16 AM
Cambrex (CBM) & CoLucid Pharmaceuticals (CLCD) Critical ContrastCambrex (CBM) & CoLucid Pharmaceuticals (CLCD) Critical Contrast
www.americanbankingnews.com - January 27 at 3:14 PM
Celgene (CELG) & CoLucid Pharmaceuticals (CLCD) Head to Head ReviewCelgene (CELG) & CoLucid Pharmaceuticals (CLCD) Head to Head Review
www.americanbankingnews.com - December 30 at 7:12 PM
Comparing CoLucid Pharmaceuticals (CLCD) & Bristol-Myers Squibb (BMY)Comparing CoLucid Pharmaceuticals (CLCD) & Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - December 15 at 7:10 PM
Comparing BioDelivery Sciences International (BDSI) & CoLucid Pharmaceuticals (CLCD)Comparing BioDelivery Sciences International (BDSI) & CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - November 23 at 1:28 PM
CoLucid Pharmaceuticals (CLCD) versus Female Health Company (The) (VERU) Financial ContrastCoLucid Pharmaceuticals (CLCD) versus Female Health Company (The) (VERU) Financial Contrast
www.americanbankingnews.com - November 3 at 1:10 AM
Lilly to Boost Migraine Pipeline with $960M CoLucid BuyoutLilly to Boost Migraine Pipeline with $960M CoLucid Buyout
finance.yahoo.com - October 5 at 11:22 AM
Eli Lilly and Company -- Moodys: Eli Lilly and Companys acquisition of pipeline-stage asset is credit negativeEli Lilly and Company -- Moody's: Eli Lilly and Company's acquisition of pipeline-stage asset is credit negative
finance.yahoo.com - October 5 at 11:22 AM
Here’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) DealHere’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) Deal
finance.yahoo.com - October 5 at 11:22 AM
Here's Why CoLucid Pharmaceuticals Inc Popped YesterdayHere's Why CoLucid Pharmaceuticals Inc Popped Yesterday
finance.yahoo.com - October 5 at 11:22 AM
Robbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. (CLCD) by Eli Lilly and Company (LLY) May Not Be in Shareholders Best InterestsRobbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. (CLCD) by Eli Lilly and Company (LLY) May Not Be in Shareholders' Best Interests
finance.yahoo.com - October 5 at 11:22 AM
COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and CompanyCOLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company
finance.yahoo.com - October 5 at 11:22 AM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCDSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCD
finance.yahoo.com - October 5 at 11:22 AM
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional InformationSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 11:22 AM
Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster OnsetAcorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
finance.yahoo.com - October 5 at 11:22 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCDINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - October 5 at 11:22 AM
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional InformationINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 11:22 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCDSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - October 5 at 11:22 AM
Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - October 5 at 11:22 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders
finance.yahoo.com - October 5 at 11:22 AM
Lilly Completes Acquisition of CoLucid PharmaceuticalsLilly Completes Acquisition of CoLucid Pharmaceuticals
finance.yahoo.com - October 5 at 11:22 AM
CoLucid Pharmaceuticals (CLCD) & Its Competitors Critical ComparisonCoLucid Pharmaceuticals (CLCD) & Its Competitors Critical Comparison
www.americanbankingnews.com - October 1 at 6:30 PM
Reviewing Dr. Reddys Laboratories (RDY) and CoLucid Pharmaceuticals (CLCD)Reviewing Dr. Reddy's Laboratories (RDY) and CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - August 31 at 4:26 AM
An experimental treatment for migraines just passed a critical studyAn experimental treatment for migraines just passed a critical study
www.businessinsider.com - May 12 at 9:56 PM
5 Top Technology Investments To Make In 20175 Top Technology Investments To Make In 2017
www.nasdaq.com - May 11 at 4:57 PM
Eli Lilly & Co. (LLY) Completes Takeover of CoLucid Pharmaceuticals (CLCD) - StreetInsider.comEli Lilly & Co. (LLY) Completes Takeover of CoLucid Pharmaceuticals (CLCD) - StreetInsider.com
www.streetinsider.com - March 1 at 9:24 PM
COLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of DelisCOLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delis
biz.yahoo.com - March 1 at 9:24 PM
Bragar Eagel & Squire, P.C. Is Investigating the Board …Bragar Eagel & Squire, P.C. Is Investigating the Board …
uk.finance.yahoo.com - January 31 at 9:47 PM
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional ...INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional ...
www.businesswire.com - January 30 at 10:14 PM
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional ...SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional ...
www.businesswire.com - January 23 at 4:37 PM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid ... - PR Newswire (press release)SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM
COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals ... - PR Newswire (press release)COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM
CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in ... - PR Newswire (press release)CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in ... - PR Newswire (press release)
www.prnewswire.com - January 19 at 10:35 PM
Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M - StreetInsider.comEli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M - StreetInsider.com
www.streetinsider.com - January 19 at 10:34 PM
CoLucid Pharmaceuticals Inc. (CLCD) Leaped To A New High On Merger NewsCoLucid Pharmaceuticals Inc. (CLCD) Leaped To A New High On Merger News
www.rttnews.com - January 19 at 5:33 PM

SEC Filings

CoLucid Pharmaceuticals (NASDAQ:CLCD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CoLucid Pharmaceuticals (NASDAQ:CLCD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CoLucid Pharmaceuticals (NASDAQ CLCD) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.